Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 780,528Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 8Ninlaro

PharmaCompass

01

Brand Name : Ninlaro

Ixazomib Citrate

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Ninlaro

arrow
APGA Annual Conference
Not Confirmed

Ixazomib Citrate

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 686

2018 Revenue in Millions : 543

Growth (%) : 26

blank

02

Brand Name : Ninlaro

Ixazomib Citrate

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Ninlaro

arrow
APGA Annual Conference
Not Confirmed

Ixazomib Citrate

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 828

2019 Revenue in Millions : 700

Growth (%) : 18

blank

03

Brand Name : Ninlaro

Ixazomib Citrate

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Ninlaro

arrow
APGA Annual Conference
Not Confirmed

Ixazomib Citrate

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 761

2020 Revenue in Millions : 794

Growth (%) : 3

blank

04

Brand Name : Ninlaro

Ixazomib Citrate

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Ninlaro

arrow
APGA Annual Conference
Not Confirmed

Ixazomib Citrate

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 743

2021 Revenue in Millions : 761

Growth (%) : -2

blank

05

Brand Name : Ninlaro

Ixazomib Citrate

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Ninlaro

arrow
APGA Annual Conference
Not Confirmed

Ixazomib Citrate

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 569

2022 Revenue in Millions : 743

Growth (%) : -13

blank

06

Brand Name : Ninlaro

Ixazomib Citrate

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Ninlaro

arrow
APGA Annual Conference
Not Confirmed

Ixazomib Citrate

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 187

2015 Revenue in Millions : 36

Growth (%) : 420

blank

07

Brand Name : Ninlaro

Ixazomib Citrate

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Ninlaro

arrow
APGA Annual Conference
Not Confirmed

Ixazomib Citrate

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 414

2016 Revenue in Millions : 200

Growth (%) : 107

blank

08

Brand Name : Ninlaro

Ixazomib Citrate

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Ninlaro

arrow
APGA Annual Conference
Not Confirmed

Ixazomib Citrate

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 526

2017 Revenue in Millions : 388

Growth (%) : 35%

blank